Melanoma spreads by hijacking two transport networks already built into your body: the lymphatic system and the bloodstream. Tumor cells first loosen their grip on neighboring skin cells, invade surrounding tissue, and then slip into nearby lymph vessels or blood vessels to travel to distant organs. The lungs, liver, brain, bone, and skin itself are the most common landing sites, though melanoma is notorious for turning up in unexpected places like the small intestine. What makes this cancer especially dangerous is a toolkit of biological tricks that let its cells switch identities, dodge immune defenses, and even prepare distant organs for their arrival before a single tumor cell shows up.
How Melanoma Cells Break Free From the Skin
Normal melanocytes sit quietly among the other cells of the epidermis, anchored in place partly by a protein called E-cadherin that acts like molecular Velcro between neighboring cells. One of the earliest steps in melanoma invasion is a swap: cells dial down E-cadherin and ramp up a related protein called N-cadherin. This switch lets melanoma cells release their hold on surrounding skin cells and instead form new connections with stromal fibroblasts, the structural cells in deeper tissue layers.1PubMed Central. YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression Researchers have found that N-cadherin also teams up with a surface receptor called α2β1 integrin, and this partnership specifically drives melanoma cells to migrate toward collagen, the scaffolding protein that fills the dermis beneath the skin surface.2PubMed Central. Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion In practical terms, the tumor trades its stay-put identity for a go-somewhere identity, and deeper tissue becomes the first destination.
Phenotype Switching Gives Melanoma Two Gears
Melanoma cells do not simply flip a permanent switch from “stationary” to “invasive.” Instead, they toggle back and forth between different states, a phenomenon researchers call phenotype switching. A cell can shift from rapid growth mode into a quieter, more mobile state that favors invasion, then revert to proliferation once it reaches a new site and needs to grow again.3PubMed Central. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance This flexibility is governed in part by a master regulatory protein called MITF, which controls over a hundred genes involved in melanocyte identity. When MITF activity is high, cells tend to proliferate and produce pigment; when MITF activity drops, cells become more invasive and stem-cell-like.4PubMed Central. Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma
This two-gear system also makes melanoma harder to treat. A drug that kills rapidly dividing cells can miss the slow, invasive ones, and vice versa. Some researchers believe phenotype switching is a major reason melanoma develops resistance to targeted therapies: the cells that survive treatment are often the ones that have already shifted into a drug-tolerant state.
Spreading Through Lymph Vessels
The lymphatic system is usually melanoma’s first highway out of the skin. Tumor cells enter thin-walled lymphatic channels near the primary melanoma and ride the slow current of lymph fluid to the nearest group of lymph nodes. To speed this process along, melanoma cells secrete signaling proteins, particularly VEGF-C and VEGF-D, that stimulate the growth of new lymphatic vessels in and around the tumor. Melanomas that produce higher levels of these signals have denser networks of lymphatic vessels and are significantly more likely to have already spread to lymph nodes at the time of diagnosis.5PubMed. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma Experimental studies have confirmed that VEGF-C production alone is enough to trigger the formation of new lymphatic vessels within tumors.6The American Journal of Pathology. Concurrent Induction of Lymphangiogenesis, Angiogenesis, and Macrophage Recruitment by Vascular Endothelial Growth Factor-C in Melanoma
This is why sentinel lymph node biopsy remains a central part of melanoma staging. A surgeon identifies the first lymph node draining the tumor site and removes it for microscopic examination. A large meta-analysis found the procedure catches about 85% of true-positive cases, and when the sentinel node comes back clean, the chance that the broader lymph node basin is actually free of disease runs between roughly 93% and 97%, depending on baseline risk.7BJS Open. Sensitivity and negative predictive value of sentinel lymph node biopsy for cutaneous melanoma for diagnosing nodal metastasis: meta-analysis of diagnostic test accuracy The procedure works reliably even in patients who have already had a wide excision of the primary melanoma, as long as the surgical site has not been extensively reconstructed.8PubMed. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma Newer mapping techniques using near-infrared fluorescence dyes are also being studied as alternatives to the traditional radioactive tracer method.9PubMed Central. Color-segmented fluorescence (“red capping”) sentinel lymph node biopsy in melanoma: a comparative analysis of node positivity rates with indocyanine green
In-Transit Metastasis
Sometimes melanoma cells get stuck between the primary tumor and the nearest lymph node, forming small deposits in the skin or subcutaneous tissue along the lymphatic drainage path. These in-transit metastases appear as small nodules, often on the limbs, and are particularly common on the lower leg. Delayed lymphatic drainage and simple gravity are thought to contribute to the higher frequency of in-transit lesions in the legs compared with other body sites.10PubMed. The European approach to in-transit melanoma lesions In-transit disease is a distinctly challenging clinical scenario because it signals that tumor cells have left the primary site but have not yet entered the bloodstream, placing it in a gray zone between local and systemic spread.
Traveling Through the Bloodstream
While lymphatic spread is the first route, bloodstream dissemination is what carries melanoma to distant organs. Once melanoma cells enter blood vessels, they face a hostile environment: shearing forces from blood flow, attacks from immune cells, and the mechanical stress of squeezing through narrow capillaries. Survival depends on several adaptations. Research has shown that circulating melanoma cells recruit white blood cells, particularly neutrophils, that help them stick to the inner lining of blood vessels. This adhesion process is influenced by shear rate in the vessels, and involves both immune cell integrins and a chemokine called IL-8 that melanoma cells coax neutrophils to respond to.11PubMed Central. Shear stress and shear rate differentially affect the multi-step process of leukocyte-facilitated melanoma adhesion In essence, melanoma exploits nearby immune cells as stepping stones to anchor itself to vessel walls at distant sites.
Preparing the Ground Before Arrival
One of the more striking discoveries in cancer biology over the past two decades is that tumors can prepare distant organs for colonization before any tumor cell physically arrives there. Melanomas release tiny membrane-bound packets called exosomes into the bloodstream. These exosomes carry proteins and genetic material that can reprogram cells at future metastatic sites, suppressing local immune responses and remodeling the tissue to be more hospitable.12PubMed Central. The Key Role of Exosomes on the Pre-metastatic Niche Formation in Tumors
Interestingly, this is not an all-or-nothing phenomenon. Exosomes from highly metastatic melanoma cells promote colonization, but exosomes from poorly metastatic melanoma cells can actually trigger the opposite effect, stimulating immune surveillance that clears arriving tumor cells. Research has found that these “non-metastatic” exosomes expand a population of patrolling monocytes in the bone marrow, which then recruit natural killer cells to the pre-metastatic site and destroy cancer cells before they can take hold.13Nature Communications. Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche The difference between a melanoma that metastasizes and one that does not may depend partly on which type of signal its exosomes send out.
Why Certain Organs Are Targeted
Melanoma does not spread to organs at random. Certain tissues attract melanoma cells more than others, and researchers believe this tropism is partly driven by chemical signals. Melanoma cells commonly display a receptor called CXCR4, which recognizes a signaling molecule (CXCL12) that is abundantly produced in the liver, lungs, and other common metastatic sites. When CXCL12 is present, melanoma cells migrate toward it. In one study, nearly 90% of melanoma liver metastases expressed CXCR4, and exposing melanoma cells to CXCL12 in the lab significantly increased their movement.14PubMed Central. Chemokine Receptor CXCR4 Expression in Patients With Melanoma and Colorectal Cancer Liver Metastases and the Association With Disease Outcome The idea is that organs producing high levels of the right chemokines essentially broadcast a homing signal that circulating melanoma cells follow.15PubMed Central. Chemokine Receptor CXCR4 Is a Novel Marker for the Progression of Cutaneous Malignant Melanomas
Beyond chemical gradients, the physical properties of blood vessel linings in different organs matter. Lab experiments comparing melanoma adhesion to endothelial cells from different organs found that adhesion was highest for liver endothelium, intermediate for lung endothelium, and lowest for brain endothelium. This hierarchy held for both primary and metastatic melanoma cells, though metastatic cells stuck more aggressively across all organ types.16PubMed Central. Role of Organ-Specific Endothelial Cells in Melanoma Adhesion Patterns
Lungs
The lungs are among the most common distant sites for melanoma spread, partly because all blood returning from the body passes through the pulmonary capillary bed, giving circulating tumor cells an early chance to lodge there. Adhesion molecules on melanoma cells, including one called gicerin, help them stick to the lining of lung blood vessels during this pass-through. Experimental blocking of gicerin reduced early lung colonization in animal models.17PubMed Central. Anti-gicerin Antibody Suppresses Early Pulmonary Metastatic Colonization of B16F10 Melanoma Cells
Liver
The liver is a particularly favorable environment for metastasis, and not just because of the CXCR4-CXCL12 signaling already described. The liver contains specialized immune cells called Kupffer cells that normally help maintain immune tolerance in the organ. Research on uveal melanoma (a subtype originating in the eye that has a striking tendency to metastasize to the liver) has found that an enzyme called ATX, naturally present on Kupffer cells, contributes to a locally immunosuppressive environment. Kupffer cells associated with ATX show increased expression of PD-L1, a molecule that essentially tells T cells to stand down. Melanoma cells arriving in the liver can exploit this built-in immune brake.18PubMed Central. Targeting liver metastases in uveal melanoma: ATX-LPA mediated immunosuppression and novel therapeutic approaches
Brain
Brain metastases are one of the most feared complications of advanced melanoma. The brain is normally protected by the blood-brain barrier, a tightly sealed layer of cells that prevents most molecules and cells from crossing into brain tissue. Melanoma cells breach this barrier in part by producing plasmin, an enzyme that degrades proteins holding the barrier together. In experimental models, blocking the plasmin system significantly reduced the number of melanoma cells that successfully crossed into the brain.19PubMed Central. The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis The relatively low adhesion of melanoma to brain endothelium compared with liver or lung endothelium may partly explain why brain metastases, while common in melanoma, tend to appear later in the course of the disease.16PubMed Central. Role of Organ-Specific Endothelial Cells in Melanoma Adhesion Patterns
Bone
Melanoma that spreads to bone does not just passively occupy the space. It actively disrupts the normal balance between bone formation and bone breakdown. Melanoma cells secrete factors that stimulate the creation of osteoclasts, the cells responsible for dissolving bone tissue. This happens through a paracrine mechanism, meaning the melanoma cells do not even need to be in direct contact with bone cells to trigger the destruction.20PubMed. Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines The result is often painful bone lesions and an increased risk of fractures in the affected areas.
Gastrointestinal Tract
Melanoma has an unusual affinity for the GI tract compared with most other cancers. Patients with GI metastases often present with vague symptoms like abdominal pain or constipation, which can delay diagnosis. The small intestine is the most frequently affected segment.21PubMed Central. Melanoma and the Gastrointestinal (GI) Tract: Maintaining a High Index of Suspicion Because these symptoms are so nonspecific, GI metastases from melanoma are sometimes discovered incidentally during imaging or surgery for unrelated complaints, and clinicians are advised to maintain a high index of suspicion in patients with a melanoma history.
How Melanoma Evades the Immune System
Melanoma is one of the most immunogenic cancers, meaning the immune system often recognizes it as foreign. Yet it still metastasizes successfully, which tells you something about the range of evasion tactics it deploys. Melanoma cells use dedifferentiation programs that resemble the process by which embryonic cells lose their specialized identities, genes that maintain stem-cell-like states borrowed from their neural crest origin, and environmental factors like low oxygen and high acidity to simultaneously promote both invasion and immune escape.22PubMed Central. Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy The fact that immune evasion and metastatic ability are driven by overlapping pathways helps explain why immunotherapy, when it works, can be so effective: reactivating the immune response can simultaneously address both problems.
Melanoma cells can also enter a dormant state at distant sites, essentially going to sleep for months or even years before reactivating. Dormant cells do not proliferate, making them invisible to therapies and immune mechanisms that target dividing cells. This dormancy is a major factor behind late recurrences. Patients who appear cured after surgery may harbor residual cells that reawaken long after treatment ends.23PubMed Central. The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma
The Neural Crest Connection
Melanocytes are not ordinary skin cells. They originate during embryonic development from the neural crest, a group of highly mobile cells that migrate throughout the embryo and give rise to diverse cell types including nerve cells, bone cells of the face, and pigment cells. Melanoma appears to reactivate portions of this ancient migration program. Multiple research groups have shown that melanoma cells express genes associated with neural crest induction and migration, and that this reactivation promotes both their plasticity and their invasiveness.24PubMed Central. Melanoma revives an embryonic migration program to promote plasticity and invasion25PubMed Central. The neural crest and cancer: a developmental spin on melanoma
One gene at the center of this story is MSX1, a transcription factor active in the embryonic neural crest. When MSX1 is turned on in melanoma cells, it pushes them toward a neural-crest-precursor-like state that is more mobile and more aggressive. In animal models, suppressing MSX1 significantly reduced metastasis.26PubMed Central. MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression This connection between melanoma and embryonic development is not just an academic curiosity. It helps explain why melanoma is so much more prone to distant spread than other skin cancers: the cells it arises from were built to travel in the first place.
Metabolic Flexibility During Spread
Tumor cells that detach from the primary site face energy challenges. They pass through environments with varying oxygen levels, nutrient supplies, and metabolic demands. Melanoma cells adapt by reprogramming their metabolism on the fly. In low-oxygen conditions, a protein called BNIP3 triggers a housekeeping process that removes damaged mitochondria. Rather than shutting down energy production, this cleanup actually makes the remaining mitochondria more efficient, boosting oxidative energy generation while reducing harmful byproducts.27PubMed Central. Hypoxia-induced BNIP3 facilitates the progression and metastasis of uveal melanoma by driving metabolic reprogramming This metabolic resilience helps circulating melanoma cells survive the transition from the oxygen-rich environment of the skin to the low-oxygen interior of a growing metastatic deposit.
Tracking Spread With Blood Tests
A rapidly developing area in melanoma care is the use of circulating tumor DNA, tiny fragments of DNA shed by tumor cells into the bloodstream. These fragments can be detected through a simple blood draw and analyzed for mutations characteristic of the patient’s melanoma. The appeal is straightforward: instead of waiting for a visible metastasis to appear on a scan, clinicians can potentially detect molecular evidence of residual or recurrent disease much earlier.28PubMed Central. Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
The results so far are encouraging. In patients treated with surgery, those with detectable ctDNA afterward had dramatically shorter times to distant metastasis compared with patients whose ctDNA cleared. Rising ctDNA levels during immunotherapy treatment predicted shorter progression-free survival, while patients with undetectable ctDNA during treatment consistently remained progression-free over the follow-up period.29PubMed. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients A systematic review confirmed that postoperative ctDNA persistence was strongly associated with recurrence and could often be detected months before clinical relapse on imaging. In most patients who remained disease-free, ctDNA cleared within weeks after surgery.30PubMed Central. Clinical Utility of Circulating Tumour DNA Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review
One limitation worth noting is that ctDNA sensitivity appears to be lower for brain metastases than for metastases at other sites, likely because the blood-brain barrier limits how much tumor DNA leaks into the general circulation.30PubMed Central. Clinical Utility of Circulating Tumour DNA Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review For now, ctDNA testing is used primarily in research settings and in select clinical scenarios for advanced melanoma, but it is moving steadily toward routine use as a monitoring tool.
Why Melanoma Resists Targeted Drugs
For patients whose melanoma carries a BRAF mutation, which accounts for roughly half of cutaneous melanomas, targeted drugs that block the BRAF protein initially work well. But resistance develops in most cases. The most common escape route involves the tumor reactivating the same growth-signaling pathway through alternative means, essentially finding a detour around the blocked road. Tumor cells can also switch to entirely different signaling pathways, such as overexpressing surface receptors that activate parallel growth circuits. The tumor microenvironment and epigenetic changes further contribute to this adaptability.31PubMed Central. BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies This resistance problem is deeply connected to the phenotype-switching ability described earlier: the same cellular plasticity that lets melanoma toggle between growth and invasion also lets it adapt to therapeutic pressure.